Clinical Evaluation of Long-term Sequelae in Patients With Severe Plasmodium Falciparum Malaria
Launched by ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE · May 27, 2025
Trial Information
Current as of June 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding the long-term effects of severe Plasmodium falciparum malaria, a serious form of malaria that can lead to significant health problems. Researchers want to learn more about the lasting issues that some patients experience after being treated for this illness, especially looking at neurological problems (like issues with thinking and memory) and other complications such as kidney failure. The study aims to compare patients who had neurological symptoms with those who did not, and it hopes to improve follow-up care for patients after they leave the hospital.
To participate in this trial, you need to be an adult (18 years or older) who was diagnosed with severe malaria and received treatment at a specific hospital between 2018 and 2024. You must have been treated with a specific medication called Artesunate IV. It's important to note that people with certain pre-existing health conditions, such as advanced neurodegenerative diseases, or those who cannot understand French, will not be eligible. Participants will have the opportunity to share their experiences, and the findings from this study could help improve care for future malaria patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female over 18 years of age
- • Have been diagnosed with severe malaria according to WHO criteria and have been treated between 1/1/2018 and 321/12/2024 at the AP-HM
- • Have been treated with Artesunate IV (MALACEF®) (at least one dose)
- • Patient who has received information about the study and has not expressed opposition
- • Patient benefiting or entitled to benefit from a social security scheme
- Exclusion Criteria:
- • Patients with advanced neurodegenerative pathology pre-existing the malaria attack
- • Subjects covered by articles L1121-5 to 1121-8 of the Public Health Code (minor patients, patients of legal age under guardianship, curatorship or safeguard of justice, patients deprived of their liberty, pregnant or breast-feeding women),
- • Persons who do not understand French
About Assistance Publique Hopitaux De Marseille
Assistance Publique - Hôpitaux de Marseille (AP-HM) is a leading public healthcare institution in France, dedicated to providing high-quality medical care and advancing research in various clinical fields. As a prominent sponsor of clinical trials, AP-HM is committed to fostering innovation and improving patient outcomes through rigorous scientific investigation. With a multidisciplinary approach, the institution collaborates with a network of healthcare professionals, researchers, and academic partners to facilitate cutting-edge studies that address critical health challenges. AP-HM's dedication to ethical standards and patient safety underscores its role as a trusted leader in clinical research and healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Marseille, , France
Patients applied
Trial Officials
Francois CREMIEUX
Study Director
APHM
Coralie L'OLLIVIER, doctor
Principal Investigator
APHM
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported